The gold standard for the diagnosis of CKD-associated bone disease is bone biopsy, an expensive and invasive procedure. Non-invasive markers of bone disease presently lack sufficient specificity and sensitivity to allow the differential diagnosis of renal osteodystrophy. New biomarkers are needed and, osteocyte-derived factors, as FGF23 and sclerostin, are promising answers.